Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Trial details
- Registry ID
- NCT02716246
- Phase
- Phase 2, Phase 3
The FDA approved UX111 (ABO-102) on 17 Sep 2026.
Drug identity checked against registry records
Also recorded as ABO-102; rebisufligene etisparvovec; scAAV9.U1a.hSGSH
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHNCT02716246 | RARE | Phase 2, Phase 3 | Recruiting | 2029-03Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-09-17Day | UX111Ultragenyx Pharmaceutical Inc · RARE | FDA CBER biologic approvalFDA approval decision | Indicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function. | Open original sourceRead source excerpt{"product": "Fayuvi rebisufligene etisparvovec-hopf", "indication": "Indicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.", "application": "125845/0", "manufacturer": "Ultragenyx Pharmaceutical Inc.", "date": "2026-09-17"} First seen: 03 Nov 2026 · Evidence last checked: 03 Nov 2026 |